zonisamide has been researched along with Dyskinesia, Drug-Induced in 4 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of L-DOPA plus ZNS in PD model mice was shown to increase the duration and severity of LID compared with PD model mice that were treated with L-DOPA alone." | 1.51 | The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice. ( Nambu, A; Sano, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tohge, R | 1 |
| Kaneko, S | 2 |
| Morise, S | 2 |
| Oki, M | 2 |
| Takenouchi, N | 2 |
| Murakami, A | 1 |
| Nakamura, M | 2 |
| Kusaka, H | 2 |
| Yakushiji, Y | 1 |
| Hashizume, T | 1 |
| Tsuge, A | 1 |
| Wate, R | 1 |
| Sano, H | 1 |
| Nambu, A | 1 |
| Yabe, H | 1 |
| Choudhury, ME | 1 |
| Kubo, M | 1 |
| Nishikawa, N | 1 |
| Nagai, M | 1 |
| Nomoto, M | 1 |
4 other studies available for zonisamide and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; GABAergic N | 2021 |
Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats.
Topics: Animals; Anticonvulsants; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Gene E | 2017 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopam | 2019 |
Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsan | 2009 |